{"prompt": "['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 3.0', 'CONFIDENTIAL', 'BCX7353-302', 'study visit, up to and including Week 48, except Weeks 2 and 26. Once a subject completes or', 'discontinues the study, the site should ensure that e-diaries are returned.', 'Given that real-time access to e-diary entries for subjects is available via website access, the', 'Investigator (or designee) will proactively assess compliance, beginning during the screening', 'period. Further training on completing the e-diary should be provided if e-diary completion', 'compliance is < 90% at any point that during the study. A phone call may be necessary if', 'compliance issues are noted in between clinic visits. Scheduled phone calls during the screening', \"period and through Part 1 of the study to Week 24 are required to assess the subject's overall\", 'wellbeing, discuss compliance (if applicable), proper recording of attack details (if applicable),', 'or any usability issues with the e-diary.', 'Study staff are not permitted to make any entries into the diary.', \"In the event that a subject's e-diary becomes nonfunctional or is otherwise not available for data\", 'recording, a paper diary may be utilized for short-term HAE attack and dose recording until the', 'subject receives a replacement e-diary. Other scenarios for which the use of the paper diary', 'and/or the shipment of a replacement e-diary may be permitted, following consultation with the', 'Sponsor. During the period of paper diary use, it will be necessary for the subject to contact the', 'Investigator after each attack that occurs.', 'Subjects who discontinue study drug should continue to record the occurrence of HAE attacks in', 'their diary until the follow-up visit.', '11.4.1.2. Investigator Confirmation of Attacks', 'Sites will have real-time access to e-diary entries for their subjects, including all attack details', 'recorded, and will receive a notification for each attack that is recorded.', 'For all attacks that occur from screening through the end of Part 2, the Investigator (or', 'appropriately trained designee) will review the e-diary record of the attack details. Subjects will', 'then be contacted within approximately 2 business days of the end of the attack to discuss the', 'clinical characteristics of the attack, any questions the Investigator has on the entered data or to', 'gain additional attack details not included in the e-diary that the Investigator deems important to', 'clinically evaluate the event, as applicable. This information, in conjunction with the e-diary', 'record, will be used by the Investigator to verify or reject the event recorded in the e-diary as an', 'HAE attack. The e-diary data review, subject contact summary, and Investigator verification or', 'rejection of the attack will be documented in the source records; the Investigator attack', 'verification (confirmed or rejected) will also be recorded.', 'During the run-in period, HAE attacks used to establish eligibility must meet the following', 'stipulations, in addition to the Investigator confirmation:', 'The attacks must occur during the run-in period which is a minimum of', '14 consecutive days and a maximum of 56 consecutive days, starting on the day of', 'the Screening visit. Subjects who record 2 eligible attacks may be randomized to', 'study drug beginning on or after Day 28 of the run-in period; subjects having at least', '3 such attacks may be randomized to study drug beginning on or after Day 14 of the', 'run-in period.', '80']['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 3.0', 'CONFIDENTIAL', 'BCX7353-302', 'The attacks are unique, which is defined as an attack that does not begin within', '48 hours of the end of a previous attack.', 'The attacks must have either been treated, required medical attention or be', 'documented to cause functional impairment based on subject entry in the diary.', 'Functional impairment is defined as the subject being unable to perform their daily', 'activities without restriction (ie, subject records that they are at least slightly', 'restricted in their daily activities during their HAE attack).', 'The attacks must include symptoms of swelling. Symptoms of swelling, in addition to', 'visible swelling, may also include symptoms in the oropharyngeal or abdominal', 'regions which are indicative of internal swelling.', 'During the remainder of the screening period (after eligibility has been established during the', 'run-in period but prior to randomization), HAE attacks must meet the following stipulations to', 'be counted in the baseline attack rate calculation necessary for stratification, in addition to the', 'Investigator confirmation:', 'The attacks are unique, which is defined as an attack that does not begin within', '48 hours of the end of a previous attack.', 'The attacks must have either been treated, required medical attention or be', 'documented to cause functional impairment based on subject entry in the diary.', 'Functional impairment is defined as the subject being unable to perform their daily', 'activities without restriction (ie, subject records that they are at least slightly', 'restricted in their daily activities during their HAE attack).', 'The attacks must include symptoms of swelling. Symptoms of swelling, in addition to', 'visible swelling, may also include symptoms in the oropharyngeal or abdominal', 'regions which are indicative of internal swelling.', 'After randomization through the end of Part 2, Investigators will use their judgment to confirm', 'or reject a reported event as an HAE attack; however, all attacks must include symptoms of', 'swelling. Symptoms of swelling, in addition to visible swelling, may also include symptoms in', 'the oropharyngeal or abdominal regions which are indicative of internal swelling.', '11.4.1.3. Scheduled Telephone Contact', 'The Investigator (or designee) must call and talk to the subject at least weekly in between the', 'Screening and Baseline visits and on-treatment through Week 24 and once during Weeks 40 and', '44. Alternative forms of interactive communication such as returned email and cellular text', 'correspondence are acceptable. During all calls, the Investigator (or designee) will assess the', \"subject's overall wellbeing, discuss compliance (if applicable), proper recording of attack details\", '(if applicable), or any usability issues with the e-diary. The phone call may be omitted if the', 'subject records an attack as the Investigator must call and confirm or reject the attack.', '11.4.2.', 'Part 3', '11.4.2.1. HAE Attack Diary', 'The Sponsor will supply diaries to sites.', '81']\n\n###\n\n", "completion": "END"}